Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

December 10, 2024

Hologic names private equity executive to board of directors

A man with dark hair wears a grey suit jacket and light blue button down. Photo I Courtesy of Hologic Martin Madaus, newly-appointed member of Hologic's board of directors

Medical device manufacturer Hologic has expanded its board, electing Martin Madaus as the Marlborough-based firm’s newest member of its board of directors, effective last Friday.

Madaus serves as Hologic’s 10th director after the board agreed to increase its members with his appointment, according to a Monday filing with the U.S. Securities and Exchange Commission.

With more than three decades of experience in the diagnostics and life sciences industry, Madaus joins the board while he presently works as an operating executive at the Carlyle Group, a Washington, D.C.-based private equity company publicly traded on the Nasdaq, according to a Monday press release.

[What does 2025 hold for your business and the Central Mass. economy? Take WBJ’s Economic Forecast survey.]

"We’re delighted to welcome Martin to Hologic’s board of directors," Steve MacMillan, Hologic chairman, president, and CEO, said in the release. "With his deep industry, technical, business and international experiences, Martin represents yet another strong addition to our deep and experienced board."

Madaus has previously served as chairman and CEO at Ortho Clinical Diagnostics, a New Jersey-based medical device manufacturer, and as chairman, president, and CEO of the former Millipore Corp., a now-acquired Burlington-based life sciences company. 

He graduated with his doctor of veterinary medicine from the University of Munich and his Ph.D. in veterinary medicine from the University of Veterinary Medicine Hannover, both in Germany.

Madaus’ appointment comes as Hologic recently entered into two multi-million dollar acquisition agreements while it looks to soon shutter a Connecticut facility. 

In April, Hologic announced it planned to acquire U.K.-based breast cancer surgery technology developer Endomagnetics for $310-million; and in October, the firm entered into a $350-million definitive agreement to purchase California-based medical technology manufacturer Gynesonics. Also in October, Hologic announced it would cease operations at its Danbury, Connecticut, facility in December and incrementally lay off 86 employees by the end of February.

Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF